Lightchain Capital

Recent News

C4-logo-wht
August 14, 2024

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

READ MORE
C4-logo-wht
August 01, 2024

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

READ MORE
C4-logo-wht
July 16, 2024

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

READ MORE
DCTX_FinalLogo_ColorAndWhite_forWebsite3
July 11, 2024

Myeloma Investment Fund Invests in Dynamic Cell Therapies to Help Fuel Novel CAR-T-Cell Technologies

READ MORE
C4-logo-wht
July 08, 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

READ MORE
wugen-logo-400
June 14, 2024

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress

READ MORE
C4-logo-400
June 10, 2024

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

READ MORE
aiProteins_Final_logo300
June 05, 2024

AI Proteins Strengthens its Leadership Team with the Addition of Biopharmaceutical Industry Veteran Michael D. Krepps as Head of Corporate Strategy

READ MORE
aiProteins_Final_logo300
May 30, 2024

AI Proteins to Attend BIO 2024; Company Provides Update on Technology Platform and Programs

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group